Stock DNA
Pharmaceuticals & Biotechnology
DKK 1 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
0.00
-122.04%
0.14
Revenue and Profits:
Net Sales:
1 Million
(Quarterly Results - Dec 2024)
Net Profit:
-2 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-48.67%
0%
-48.67%
6 Months
-65.85%
0%
-65.85%
1 Year
4252.94%
0%
4252.94%
2 Years
-96.53%
0%
-96.53%
3 Years
-48.49%
0%
-48.49%
4 Years
-99.96%
0%
-99.96%
5 Years
-99.95%
0%
-99.95%
DanCann Pharma A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
54.04%
EBIT Growth (5y)
4.73%
EBIT to Interest (avg)
-6.88
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.24
Sales to Capital Employed (avg)
0.50
Tax Ratio
0.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.09
EV to EBIT
-0.10
EV to EBITDA
-0.12
EV to Capital Employed
0.10
EV to Sales
0.19
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-102.91%
ROE (Latest)
-122.04%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'24 - QoQ
Dec'24
Sep'24
Change(%)
Net Sales
1.40
1.90
-26.32%
Operating Profit (PBDIT) excl Other Income
-1.60
-0.90
-77.78%
Interest
0.10
0.30
-66.67%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.20
-2.90
24.14%
Operating Profit Margin (Excl OI)
-1,544.40%
-766.00%
-77.84%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2024 is -26.32% vs -51.28% in Sep 2024
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2024 is 24.14% vs -383.33% in Sep 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
7.40
6.10
21.31%
Operating Profit (PBDIT) excl Other Income
-5.20
-13.20
60.61%
Interest
1.30
2.30
-43.48%
Exceptional Items
0.00
-43.80
100.00%
Consolidate Net Profit
-8.30
-62.30
86.68%
Operating Profit Margin (Excl OI)
-976.10%
-2,725.70%
174.96%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 21.31% vs 7.02% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 86.68% vs -286.96% in Dec 2023
About DanCann Pharma A/S 
DanCann Pharma A/S
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






